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Leptin is an adipose tissue-derived hormone that has been involved in hypothalamic and
systemic inflammation, altered food-intake patterns, and metabolic dysfunction in obese
mice. However, it remains unclear whether leptin has a relationship with parameters
of systemic inflammation and metabolic dysfunction in humans. We thus evaluated in
a cross-sectional study the circulating levels of leptin in 40 non-obese and 41 obese
Mexican individuals, examining their relationship with tumor necrosis factor alpha (TNF-α),
interleukin (IL) 12, IL-10, central obesity, serum glucose and insulin levels, and serum
triglyceride and cholesterol concentrations. Circulating levels of leptin, TNF-α, IL-12, IL-10,
and insulin were measured by ELISA, while concentrations of glucose, triglyceride,
and cholesterol were determined by enzymatic assays. As expected, serum levels of
leptin exhibited a significant elevation in obese individuals as compared to non-obese
subjects, showing a clear associationwith increased body mass index (r = 0.4173), central
obesity (r = 0.4678), and body fat percentage (r = 0.3583). Furthermore, leptin also
showed a strong relationship with serum TNF-α (r = 0.6989), IL-12 (r = 0.3093), and IL-10
(r = −0.5691). Interestingly, leptin was also significantly related with high concentrations
of fasting glucose (r = 0.5227) and insulin (r = 0.2229), as well as elevated levels of insulin
resistance (r = 0.3611) and circulating triglyceride (r = 0.4135). These results suggest
that hyperleptinemia is strongly associated with the occurrence of low-grade systemic
inflammation and metabolic alteration in obese subjects. Further clinical research is still
needed to determine whether hyperleptinemia may be a potential marker for recognizing
the advent of obesity-related metabolic disorders in human beings.
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INTRODUCTION
Obesity is now considered a major health problem worldwide,
with a growing prevalence in the Mexican population (Olaiz-
Fernández et al., 2006; Popkin, 2011). Obese people show a
higher risk to develop type 2 diabetes (T2D), coronary heart dis-
ease, stroke, arterial hypertension, non-alcoholic steatohepatitis
(NASH), and other obesity-related metabolic disorders (Ritchie
and Connell, 2007). These pathologies have been recently asso-
ciated with a low-grade systemic inflammatory state (Odegaard
and Chawla, 2008), characterized by altered circulating levels of
inflammatory mediators in the obese subject, including tumor
necrosis factor alpha (TNF-α), interleukin (IL-) 12, C-reactive
protein (CRP), and IL-10 (Rush et al., 2007; Bremer et al.,
2011). TNF-α has been shown to increase with adiposity in
mice and human beings (Steinberg et al., 2006). Circulating
concentrations of IL-12 and CRP are elevated in overweight
and obese individuals, exhibiting a significant association with
increased body mass index (BMI) and waist circumference, as
well high glucose and triglyceride levels (Visser et al., 1999;
Suarez-Alvarez et al., 2013). On the contrary, serum IL-10 lev-
els have been shown to decrease in high-fat diet fed-mice (Gotoh
et al., 2012). As it can be seen, circulating proinflammatory fac-
tors have received growing attention since they could play a
major role in mediating the low-grade inflammatory state, which
seems to decisively contribute to the advent of obesity-related
metabolic disorders (Ritchie and Connell, 2007; Bertola et al.,
2010).
Leptin is an adipose tissue-derived hormone belonging to the
class-I helical cytokine family (Trinchieri, 2003). Leptin has been
shown to regulate food-intake and energy expenditure in both
rodents and humans (Houseknecht et al., 1998). Interestingly, cir-
culating levels of leptin have been shown to increase in high-fat
diet fed-mice and obese subjects, leading to a state of hyper-
leptinemia (Maffei et al., 1995; Lin et al., 2000). However,
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although hyperleptinemia strongly correlates with parameters of
low-grade systemic inflammation and metabolic dysfunction in
animal models of obesity (Munzberg, 2008; Arruda et al., 2011;
Stienstra et al., 2011), they show controversial results in human
beings. For instance, it has been reported that serum leptin is
augmented in obese individuals with metabolic syndrome (MetS)
that also show an elevation in the plasma levels of CRP (Kim
et al., 2006). In contrast, obese non-diabetic women subjected
to a caloric restriction diet show decreased values in plasma lep-
tin without exhibiting a significant diminution in the circulating
levels of TNF-α (Agueda et al., 2012). In the same sense, in
obese adolescents leptin has been shown to rise independently
of the levels of insulin resistance and TNF-α (Aguilar et al.,
2012; Cohen et al., 2012). As it can be seen, it is still unclear
whether hyperleptinemia has an association with the occurrence
of low-grade systemic inflammation and metabolic dysfunction
in humans.
We thus studied the serum levels of leptin in non-obese and
obese Mexican individuals, examining their possible relationship
with parameters of low-grade systemic inflammation (TNF-α,
IL-12, and IL-10) and metabolic alteration (elevated serum glu-
cose and insulin, increased level of insulin resistance, high triglyc-
eride and cholesterol concentrations, as well as increasing waist
circumference and body fat percentage).
MATERIALS AND METHODS
SUBJECTS
A total of 81 apparently healthy Mexican adult volunteers
from the south-central region of Mexico were included in the
study. All of the participants provided written informed con-
sent, previously approved by an institutional review board of
the General Hospital of Mexico “Dr. Eduardo Liceaga,” which
guaranteed that the study was conducted in accordance with the
principles described at the Helsinki Declaration. Subjects were
excluded from the study if they had previous or recent diagno-
sis of diabetes mellitus, cardiovascular diseases, chronic hepatic
or renal disease, blood pressure higher than 140/90mm Hg,
inflammatory or autoimmune disorders, acute or chronic infec-
tious diseases, cancer, and endocrine disorders. We additionally
excluded pregnant or lactating women, subjects under any kind of
cardiometabolic medication including anti-inflammatory, anti-
aggregant, and anti-hypertensive drugs, and subjects without
having an 8–12 h overnight fasting. All of the individuals enrolled
into the study received full medical evaluation, including the
achievement of clinic history and physical examination by a
physician.
MEASUREMENT OF ANTHROPOMETRIC PARAMETERS
According to the World Health Organization criteria for BMI, all
of the participants were divided into two groups: control non-
obese subjects (BMI 18.5–24.9 kg/m2) and obese subjects (BMI≥
30 kg/m2), where BMI resulted of dividing weight by height
squared (kg/m2). Waist circumference was obtained from each
study subject, considering the midpoint between the lower rib
margin and the iliac crest, using a conventional tape in centime-
ters (cm). For women, abdominal obesity was considered when
their waist circumference were 80 cm or higher, whereas for men
it was considered when their waist circumference were 94 cm or
higher. Percentage of body fat was individually recorded by using
a body composition analyzer (TANITA®, Body Composition
Analyzer, Model TBF-300A, Tokyo, Japan).
MEASUREMENT OF METABOLIC PARAMETERS
Blood samples were individually taken after overnight fast-
ing, and collected into pyrogen-free tubes (VacutainerTM, BD
Diagnostics, NJ, USA) at room temperature. Collection tubes
were then centrifuged at 1000 g/4◦C for 30min, and serum sam-
ples obtained and stored at −80◦C in numerous aliquots until
use. Total cholesterol and triglyceride were individually mea-
sured in triplicate by an enzymatic assay according to manufac-
turer’s instructions (Roche Diagnostics, Mannhein, Germany).
Serum insulin levels were individually determined in triplicate
by means of the enzyme-linked immunosorbent assay (ELISA),
following the manufacturer’s instructions (Abnova Corporation,
Taiwan). Serum glucose levels were individually determined in
triplicate by the glucose oxidase assay, following the manu-
facturer’s instructions (Megazyme International, Ireland). The
estimate of insulin resistance was individually determined by
means of the HOMA-IR, as follows: fasting insulin concentra-
tion (mU/L) × fasting glucose concentration (mmol/L) divided
by 22.5.
MEASUREMENT OF LEPTIN AND LOW-GRADE SYSTEMIC
INFLAMMATION PARAMETERS
Blood samples were individually taken after overnight fast-
ing, and collected into pyrogen-free tubes (VacutainerTM, BD
Diagnostics, NJ, USA) at room temperature. Collection tubes
were then centrifuged at 1000 g/4◦C for 30min, and serum sam-
ples obtained and stored at−80◦C in numerous aliquots until use.
Serum levels of leptin, TNF-α, IL-10, and IL-12 were determined
in triplicate by ELISA, following the manufacturer’s instructions
(Peprotech, Mexico).
STATISTICAL ANALYSIS
Data from anthropometric and metabolic parameters were ana-
lyzed by using the Student’s t-test for determining significant
differences. Data from leptin, TNF-α, IL-10, and IL-12 were ana-
lyzed by means of using the Mann-Whitney U-test for determin-
ing significant differences. The Spearman’s correlation coefficient
was performed for examining the relationship of leptin with
anthropometric, metabolic, and inflammatory parameters. All of
the studied groups were matched by gender and age. Statistical
analysis was performed using the GraphPad Prism 5 software.
Differences were considered significant when p < 0.05.
RESULTS
A total of 40 non-obese controls and 41 obese subjects were
included in the study. No significant differences were observed
in age (for non-obese controls mean age 29.9 ± 10.35 years,
whereas for obese subjects mean age 34.9 ± 10.24 years), and
women/men proportion (22 women and 18 men in the non-
obese control group, and 20 women and 21 men in the obesity
group) in the studied groups (Table 1). In contrast, BMI, waist
circumference, body fat percentage, fasting blood glucose and
insulin, circulating levels of triglyceride and cholesterol, and
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Table 1 | Anthropometric, metabolic, and inflammatory
characteristics of the study subjects.
Non-obese Obese P-value
Gender (W/M) 22/18 20/21 N.S.
Age (years) 29.9 ± 10.3 34.9 ± 10.2 N.S.
BMI (kg/m2) 22.6 ± 1.8 33.7 ± 3.4 p < 0.0001
Waist circumference
(cm)
79.6 ± 6.5 107.4 ± 9.9 p < 0.0001
Body fat percentage 24.6 ± 8.2 37.6 ± 6.9 p < 0.05
Fasting blood glucose
(mmol/L)
4.3 ± 0.1 5.89 ± 0.3 p < 0.0001
Fasting blood insulin
(mU/L)
12.6 ± 1.4 15.5 ± 6.7 p = 0.0088
HOMA-IR 2.4 ± 0.3 4.08 ± 1.8 p < 0.0001
Total cholesterol (mg/dL) 192.8 ± 10.1 198.1 ± 10.3 p = 0.0219
Total triglyceride (mg/dL) 137.5 ± 9.1 251.9 ± 14.4 p < 0.0001
TNF-α (pg/mL) 271.8 ± 28.05 322.9 ± 58.5 p < 0.05
IL-12 (pg/mL) 272.9 ± 13.6 381.5 ± 59.8 p < 0.0001
IL-10 (pg/mL) 1145.2 ± 214.6 840.8 ± 96.5 p < 0.0001
Abbreviations: W, women; M, men; BMI, body mass index; HOMA-IR, homeo-
static model assessment-insulin resistance; TNF-α, tumor necrosis factor alpha;
IL, interleukin; N.S., non-significant differences.
Data are presented as mean ± standard deviation.
Differences were considered significant when p < 0.05.
serum concentrations of TNF-α and IL-12 were clearly increased
in obese individuals as comparing with non-obese control sub-
jects (Table 1). Concomitantly, serum levels of IL-10 were sig-
nificantly lower in obese individuals than in non-obese subjects
(Table 1). It merits to mention that BMI was clearly correlated
with waist circumference (r = 0.9297, p < 0.0001) and body fat
percentage (r = 0.7655, p < 0.0001) in our study population. In
a similar way, there was also a significant association between
waist circumference and body fat percentage (r = 0.7655, p <
0.0001).
In accordance with previous reports, circulating levels of lep-
tin were significantly increased in obese subjects when comparing
to non-obese control individuals. In terms of BMI, leptin exhib-
ited a significant 1.5-fold increase in obese subjects as comparing
with normal weight controls (Figure 1A). In obese individuals,
the mean value of leptin was 1256.1 ± 207.7 ng/mL, whereas
in the non-obese group it was around 812.1 ± 417.8 ng/mL
(Figure 1A). Interestingly, serum values of leptin still showed a
significant elevation when examining in subjects with abdominal
obesity (Figure 1B). For this case, the mean value of leptin in sub-
jects with abdominal obesity was 1141.8 ± 343.6 ng/mL, while
it decreased to 858.3 ± 419.6 ng/mL in individuals exhibiting a
normal waist perimeter (Figure 1B).
As expected, our results show that circulating levels of leptin
increase with obesity-related anthropometric parameters. Indeed,
leptin was significantly correlated with increased BMI (r =
0.4173, p = 0.0001), central obesity (r = 0.4678, p < 0.0001),
and body fat percentage (r = 0.3583, p = 0.0010) (Figures 2A–C,
respectively). Furthermore, leptin also exhibited a clear asso-
ciation with parameters of metabolic alteration. In this sense,
FIGURE 1 | Serum levels of leptin in obese and non-obese individuals.
(A) Circulating leptin levels were assessed in normal weight and obese
subjects, defining obesity according to the World Health Organization
criteria for body mass index. In our study population, serum leptin was also
evaluated in terms of abdominal obesity (B). For women, abdominal obesity
was considered when the waist circumference was 80 cm or higher,
whereas for men, it was considered when the waist circumference was
94 cm or higher. Data are expressed as mean ± S. E. Differences were
considered significant when p < 0.05.
FIGURE 2 | Statistical correlation between serum levels of leptin and
anthropometric parameters of obesity. Serum levels of leptin were
positively associated with body mass index (BMI) (A), waist circumference
(B), and body fat percentage (C). Coefficients (r) and P -values were
calculated by using the Spearman’s correlation model. The correlation level
was considered significant when p < 0.05.
serum leptin was significantly related with increased levels of
blood glucose (r = 0.5227, p < 0.0001) and insulin (r = 0.2229,
p = 0.0455) (Figures 3A,B, respectively). There was also a signifi-
cant relationship between leptin and the level of insulin resistance,
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FIGURE 3 | Statistical correlation of the serum levels of leptin with
fasting blood glucose, fasting blood insulin, and insulin resistance.
Serum concentrations of leptin exhibited a positive significant relationship
with high levels of glucose (A) and insulin (B), as well increased insulin
resistance (C). The level of insulin resistance was estimated using the
HOMA-IR index, which results of multiplying fasting insulin concentration
(mU/L) by fasting glucose concentration (mmol/L), then divided by the
constant 22.5. Coefficients (r) and P -values were calculated by the
Spearman’s correlation model. The correlation level was considered
significant when p < 0.05.
estimated by means of the HOMA-IR (r = 0.3611, p < 0.0009)
(Figure 3C). Interestingly, leptin had a positive association with
increased triglyceride levels (r = 0.4135, p = 0.0001), but not
with total cholesterol (Figures 4A,B, respectively).
Besides having significant relationships with anthropomet-
ric and biochemical parameters associated with obesity-related
metabolic alterations, hyperleptinemia also showed a strong
relation with markers of low-grade systemic inflammation in
the study subjects. In fact, circulating leptin was positively cor-
related with serum levels of TNF-α (r = 0.6989, p < 0.0001)
and IL-12 (r = 0.3093, p = 0.0050) (Figures 5A,B), whereas a
significant negative relationship between leptin and IL-10 was
observed in the study population (r = −0.5691, p < 0.0001)
(Figure 5C).
DISCUSSION
As mentioned, it has been consistently shown that serum con-
centrations of leptin increase in high-fat diet fed-mice and obese
humans. In mice, hyperleptinemia is related to hyperphagia and
FIGURE 4 | Statistical correlation of the serum levels of leptin with
total triglyceride and cholesterol levels. Serum concentrations of leptin
showed a positive significant relationship with high levels of triglycerides
(A), but not with total cholesterol (B). Coefficients (r) and P -values were
calculated by the Spearman’s correlation model. The correlation level was
considered significant when p < 0.05.
FIGURE 5 | Statistical correlation of the serum levels of leptin with
parameters of low-grade systemic inflammation. Serum
concentrations of leptin showed a positive significant relationship with
increased serum levels of TNF-α (A), and IL-12 (B). At the same
time, hyperleptinemia exhibited a significant inverse association with
circulating concentrations of IL-10 (C). Coefficients (r) and P -values
were calculated by the Spearman’s correlation model. The correlation
level was considered significant when p < 0.05.
fat depot augmentation, while it is associated with increased
white adipose tissue (WAT) mass and body weight gain in human
beings (Stanley et al., 2005). However, recent experimental evi-
dence from animal models of obesity suggests that leptin is
not only a marker of weight gain but also seems to have a
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relationship with developing a systemic state of low-grade inflam-
mation and metabolic disturbance. In fact, obese mice exhibiting
hyperleptinemia show increased plasma levels of inflammatory
cytokines (Dube et al., 2008; Yang et al., 2010; Enos et al., 2013),
accompanied by numerous metabolic disorders including hyper-
glycemia (Yang et al., 2010), hyperinsulinemia (Stienstra et al.,
2011), hyperlipidemia (Kang et al., 2011), liver steatosis (Shih
et al., 2010), and insulin resistance (Yang et al., 2010). Taking
this experimental evidence into account, it is important to eval-
uate whether hyperleptinemia could also be associated to the
establishment of systemic inflammation and metabolic dysfunc-
tion in human beings with high metabolic risk, such as obese
individuals.
In humans, the relationship of leptin with a state of metabolic
dysfunction has been barely studied, showing inconclusive results
to date. Indeed, a study conducted in a group of obese ado-
lescents revealed that high serum levels of leptin correlate with
increased BMI and waist circumference, without having a sig-
nificant relation with the insulin resistance level (Aguilar et al.,
2012). In contrast, recent data from a cross-sectional survey
conducted in obese adults demonstrated that hyperleptinemia
is clearly associated with BMI, hyperinsulinemia, and insulin
resistance (Martins Mdo et al., 2012). Our results are con-
sistent with the last study, since high levels of leptin were
significantly correlated with hyperglycemia, hyperinsulinemia,
increased HOMA-IR, and hypertriglyceridemia in our study
population. A possible explanation to understand this appar-
ently controversial finding may involve the age of the sub-
jects included in each study. As it is widely known, the level
of sex-steroid hormones reaches a plateau during maturity, in
comparison to both childhood and adolescence where numer-
ous hormonal variations are normally observed (Stanhope and
Brook, 1988; Rogol, 2004). Interestingly, it has been recently
reported that sex-steroid hormones are able to upregulate the
leptin expression in human and rat cells (Feng et al., 2011;
Gambino et al., 2012). Therefore, it is feasible to expect that syn-
thesis of leptin may be enhanced during adulthood, which may
contribute to decrease the leptin levels in children/adolescents
in comparison with adults. However, additional clinical studies
considering the influence of sex-steroid hormones upon the sys-
temic levels of leptin are necessary in order to address major
conclusions.
An interesting finding in this cross-sectional study involves
the relationship of hyperleptinemia with a systemic state of low-
grade inflammation in obese human beings. A recent study
demonstrated that leptin is overexpressed in the subcutaneous
adipose tissue (SAT) of obese individuals with MetS, as com-
paring with SAT from healthy obese subjects and non-obese
individuals (Farb et al., 2011). Furthermore, increasing in the
leptin expression is accompanied by macrophage infiltration
and overexpression of proinflammatory cytokines such as IL-
1β, IL-6, and IL-8 in the SAT of those same patients (Bremer
et al., 2011; Farb et al., 2011). Consistent with this previ-
ous study, our results show that hyperleptinemia is signifi-
cantly associated with high serum levels of TNF-α and IL-12,
as well as reduced concentrations of IL-10 in subjects with
central obesity, hyperglycemia, increased insulin resistance, and
hypertriglyceridemia. IL-12 is a cytokine with the ability to
induce synthesis of interferon-gamma (IFN-γ) in T cells and
natural killer cells (Trinchieri, 2003). IFN-γ is a key media-
tor in releasing of TNF-α by classically activated macrophages
(Odegaard and Chawla, 2008). Taking into consideration that
serum IFN-γ has been shown to increase during obesity (Azar
Sharabiani et al., 2011), it is conceivable to expect a positive
relationship among TNF-α, IL-12, and leptin in our study pop-
ulation. Another intriguing issue concerning the positive asso-
ciation among leptin, TNF-α, and IL-12, involves the ability of
leptin to regulate the expression of inflammatory cytokines. It
has been recently reported that leptin is able to stimulate the
in vitro production of TNF-α and IL-1β in human mononu-
clear cells (Tsiotra et al., 2013). Thus, it is now proposed that
high levels of leptin may induce the production of proinflamma-
tory cytokines in obese people, contributing in this way to the
systemic inflammation observed in these subjects. Nevertheless,
before establishing a possible cause-and-effect relation among
leptin, TNF-α, and IL-12 in the scenario of obesity, additional
prospective clinical research is required. Moreover, consistent
with the installation of a systemic state of low-grade inflam-
mation, we observed a significant reduction in the circulating
levels of IL-10 in obese individuals as comparing with non-obese
subjects. IL-10 is a cytokine with potent anti-inflammatory prop-
erties in mice and humans (Saraiva and O’garra, 2010). However,
the role of IL-10 during systemic inflammation and metabolic
dysfunction is still poorly understood (Formoso et al., 2012;
Tajik et al., 2012). For this reason, it is important to mention
that the present work is one of the first contributions show-
ing a significant inverse correlation between serum IL-10 and
hyperleptinemia in obese individuals. Collectively, these find-
ings suggest that obesity-related hyperleptinemia is accompanied
by a low-grade inflammatory profile, characterized by increased
circulating levels of TNF-α and IL-12, and reduced concen-
trations of IL-10. Whether hyperleptinemia is cause or conse-
quence of the systemic inflammatory milieu in humans, is a
matter worthy of being considered in further basic and clinical
studies.
Present results demonstrate that high circulating levels of
leptin are significantly associated with a systemic state of low-
grade inflammation and metabolic dysfunction in obese subjects.
Additional prospective clinical studies are still required to eval-
uate whether hyperleptinemia may be used as a marker for
recognizing the advent of obesity-related metabolic disorders in
human beings.
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